Rosiglitazone Facilitates Angiogenic Progenitor Cell Differentiation Toward Endothelial Lineage: A New Paradigm in Glitazone Pleiotropy

Circulation

Volumn 109, Issue 11, 2004, Pages 1392-1400

  Wang, Chao Hung ^a,c   Ciliberti, Nadia ^b   Li, Shu Hong ^a   Szmitko, Paul E ^a   Weisel, Richard D ^a   Fedak, Paul W M ^a   Al Omran, Mohammed ^a   Cherng, Wen Jin ^c   Li, Ren Ke ^a   Stanford, William L ^b   Verma, Subodh ^a,d  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cells; Endothelium, vascular; Receptors, cytoplasmic and nuclear; Thiazolidinediones; Vessels

Indexed keywords

ALPHA ACTIN; DELTA15 PROSTAGLANDIN J2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN J2; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANGIOPLASTY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATTENUATION; BONE MARROW CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; EMBRYO CELL; ENDOTHELIUM CELL; FEMORAL ARTERY FLOW; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PERIPHERAL CIRCULATION; PLEIOTROPY; PRIORITY JOURNAL; RESTENOSIS; STEM CELL; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL LINEAGE; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; HUMANS; HYPERPLASIA; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MULTIPOTENT STEM CELLS; MUSCLE CELLS; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PHYSIOLOGIC; RADIATION CHIMERA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT PROTEINS; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUNICA INTIMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 12144289791     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000123231.49594.21     Document Type: Article

References (29)

1. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403-409.
2. Szmitko PE, Fedak PWM, Weisel RD, et al. Endothelial progenitor cells: new hope for a broken heart. Circulation. 2003;107:3093-3100.
3. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105:3017-3024.
4. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res. 2002;90:1189-1196.
5. Ema M, Faloon P, Zhang WJ, et al. Combinatorial effects of Flk1 and Tall on vascular and hematopoietic development in the mouse. Genes Dev. 2003;17:380-393.
6. Wang CH, Weisel RD, Liu PP, et al. Glitazones and heart failure: critical appraisal for the clinician. Circulation. 2003;107:1350-1354.
7. Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52-57.
8. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235-238.
9. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
10. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108:1917-1923.
11. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897-1905.
12. Hannan KM, Dilley RJ, De Dios ST, et al. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler Thromb Vasc Biol. 2003;23:762-768.
13. Phillips JW, Barringhaus KG, Sanders JM, et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation. 2003;108:1994-1999.
14. Hadjantonakis AK, Nagy A. FACS for the isolation of individual cells from transgenic mice harboring a fluorescent protein reporter. Genesis. 2000;27:95-98.
15. Law RE, Goetze S, Xi XP, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311-1318.
16. Hidaka M, Stanford WL, Bernstein A. Conditional requirement for the Flk-1 receptor in the in vitro generation of early hematopoietic cells. Proc Natl Acad Sci U S A. 1999;96:7370-7375.
17. Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-812.
18. Clay CE, Namen AM, Atsumi G, et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 1999;20:1905-1911.
19. Bui T, Straus DS. Effects of cyclopentenone prostaglandins and related compounds on insulin-like growth factor-I and Waf1 gene expression. Biochim Biophys Acta. 1998;1397:31-42.
20. Winnett G, van Hagen D, Schrey M. Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy. Int J Cancer. 2003;103:600-605.
21. Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol. 2001;21:1891-1895.
22. De Dios ST, Hannan KM, Dilley RJ, et al. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J Diabetes Complications. 2001;15:120-127.
23. Yamakawa K, Hosoi M, Koyama H, et al. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun. 2000;271:571-574.
24. Hupfeld CJ, Weiss RH. TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. Am J Physiol. 2001;281:E207-E216.
25. Galli A, Crabb D, Price D, et al. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hepatology. 2000;31:101-108.
26. Goetze S, Xi XP, Kawano H, et al. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol. 1999;33:798-806.
27. Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res. 2001;88:167-174.
28. Emoto M, Anno T, Sato Y, et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes. 2001;50:1166-1170.
29. Badorff C, Brandes RP, Popp R, et al. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation. 2003;107:1024-1032.